MEDIVIR AB - INTERIM REPORT JANUARY - MARCH 2024 [Yahoo! Finance]
Tango Therapeutics, Inc. (NASDAQ: TNGX) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating on the stock.
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Tango Therapeutics, Inc. (NASDAQ: TNGX) had its price target raised by analysts at HC Wainwright from $16.00 to $17.00. They now have a "buy" rating on the stock.
Tango Therapeutics, Inc. (NASDAQ: TNGX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $18.00 price target on the stock.